Financial Data and Key Metrics Changes - Research and development expenses for Q4 2025 were $153.5 million, up from $31 million in Q4 2024, primarily due to expenses related to two phase 3 clinical trials and increased stock-based compensation [7] - General and administrative expenses decreased to $11.3 million in Q4 2025 from $15.3 million in Q4 2024, mainly due to reduced legal and patent service expenses [8] - The net loss for Q4 2025 was $157.7 million or $1.38 per share, compared to a net loss of $35.4 million or $0.32 per share in Q4 2024 [8] - For the full year 2025, research and development expenses totaled $345 million, up from $101.6 million in 2024, driven by increased clinical study costs [9] - The full year net loss was $358.5 million or $3.19 per share, compared to a net loss of $110 million or $1.01 per share in 2024 [9][10] - Cash, cash equivalents, and short-term investments at year-end 2025 were $706 million, down from $903 million at the end of 2024 [10] Business Line Data and Key Metrics Changes - The company advanced its lead obesity program VK2735, with both subcutaneous and oral formulations showing promising efficacy and safety in clinical trials [11][12] - The phase 3 VANQUISH program for VK2735 includes two studies, with VANQUISH-1 fully enrolled ahead of schedule and VANQUISH-2 nearing completion [4][15] - The oral VK2735 program also achieved positive results in a phase 2 study, demonstrating significant weight loss compared to placebo [18][20] Market Data and Key Metrics Changes - The market for obesity treatments is evolving rapidly, with increasing interest in new therapies, as evidenced by the uptake of other oral peptides [17][80] - The company is exploring various commercial strategies to adapt to the changing landscape, including potential partnerships with emerging market players [35][39] Company Strategy and Development Direction - Viking is focused on advancing its VK2735 program through phase 3 trials for both subcutaneous and oral formulations, aiming to introduce the first dual GLP-1 and GIP coagonist therapies [25][26] - The company has signed a comprehensive manufacturing agreement with CordenPharma to support large-scale production of VK2735, positioning itself for significant revenue opportunities [6][24] - The company is also developing a series of novel amylin receptor agonists, with plans to file an IND for this program soon [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate the evolving obesity treatment landscape and emphasized the importance of maintaining a strong balance sheet to support ongoing clinical trials [25][40] - The company anticipates that both the subcutaneous and oral VK2735 programs will enter phase 3 trials in 2026, with results from the maintenance study expected later this year [26][23] Other Important Information - The company appointed Neil Aubuchon as Chief Commercial Officer to lead its commercial strategy, bringing extensive industry experience [6][24] - Viking's operational focus includes expanding staffing in clinical, supply chain, and manufacturing roles to support its growing pipeline [24] Q&A Session Summary Question: Will a phase 3 study be needed in patients with diabetes? - Management indicated that the design elements for the phase 3 study will likely parallel the VANQUISH studies, but specific details will be disclosed closer to launch [30][31] Question: How will the evolving obesity market influence the go-to-market strategy? - Management acknowledged the rapid changes in the market and emphasized the flexibility to adapt the commercial strategy accordingly [35][39] Question: Is the $700 million cash sufficient for developing oral VK2735? - Management confirmed that the cash is sufficient to cover expenses for developing both the oral and subcutaneous VK2735 programs [40] Question: What are the expectations for the maintenance study? - Management outlined that success would involve continued weight loss or maintenance of weight after transitioning to less frequent dosing regimens [49] Question: Will the autoinjector be introduced in the maintenance study? - Management clarified that the maintenance study will use vial and syringe administration, not the autoinjector [97]

Research and Development - The company incurred $345.0 million in research and development expenses for the year ended December 31, 2025, primarily related to the VK2735 Phase 2 VENTURE clinical trial and other ongoing studies [435]. - The VK2735 Phase 2 VENTURE study demonstrated statistically significant reductions in mean body weight after 13 weeks, with reductions up to 14.7% from baseline for patients receiving VK2735 [415]. - The Phase 1 trial of VK2735 was completed in March 2023, leading to the initiation of the Phase 2 VENTURE study in September 2023 [414]. - The company plans to file an Investigational New Drug application for the new Dual Amylin and Calcitonin Receptor Agonist (DACRA) program in the first quarter of 2026 [421]. - The VOYAGE study of VK2809 achieved its primary endpoint, with significant reductions in liver fat content from baseline to Week 12 compared to placebo [427]. - In June 2024, 75% of VK2809-treated patients achieved NASH/MASH resolution with no worsening of fibrosis, compared to 29% for placebo (p=0.0001) [428]. - The Phase 1b clinical trial of VK0214 showed significant reductions in plasma levels of very long chain fatty acids compared to placebo [431]. - The company is dynamically managing its research and development expenses based on scientific data and market potential [436]. - Research and development expenses increased to $344,955,000 in 2025 from $101,644,000 in 2024, representing a 239.4% increase [454]. - The increase in research and development expenses was primarily due to clinical studies costs rising by $202.7 million and manufacturing costs increasing by $32.5 million [454]. - Future research and development expenses will depend on the clinical success of drug candidates and ongoing assessments of their commercial potential [438]. Financial Performance - The company has not generated any revenue to date and does not expect to until regulatory approval and commercialization of its drug candidates [434]. - General and administrative expenses decreased slightly to $48,387,000 in 2025 from $49,277,000 in 2024, a reduction of 1.8% [456]. - Other income, net decreased to $33,703,000 in 2025 from $40,958,000 in 2024, reflecting a decline of 17.7% [458]. - As of December 31, 2025, the company had cash, cash equivalents, and short-term investments totaling $705.7 million, expected to fund operations through at least Q1 2027 [461]. - The company has incurred operating losses since inception and has not generated any revenues to date [462]. - The company expects to continue increasing general and administrative expenses to support research and development activities, including salaries and stock-based compensation [439]. - For the year ended December 31, 2025, net cash used in operating activities was $278.7 million, reflecting net losses adjusted by non-cash charges [470]. - The company anticipates continued losses as it develops drug candidates and seeks regulatory approvals, indicating a need for additional capital [475]. Capital and Financing - The company has entered into an At-The-Market Equity Offering Sales Agreement with a total offering price of up to $125 million, resulting in net proceeds of approximately $13.6 million from shares sold [463]. - A stock repurchase program was authorized in March 2022, allowing the company to repurchase up to $50 million in shares, with 729,034 shares repurchased by March 2024 [464]. - In April 2023, the company completed a public offering of 19,828,300 shares at $14.50 per share, raising gross proceeds of $287.5 million [465]. - In March 2024, the company completed another public offering of 7,441,650 shares at $85.00 per share, resulting in net proceeds of $597.1 million [468]. - The company has a stock repurchase program authorized for up to $250.0 million, effective February 27, 2025 [469]. - From the ATM Offering, the company sold 3,556,911 shares, with remaining gross proceeds of up to $75.7 million available for future sales [467]. - In 2025, net cash provided by financing activities was $76.4 million, primarily from the ATM Offering and option exercises [473]. - The company expects to finance future cash needs through public or private equity or debt offerings, though availability on acceptable terms is uncertain [475]. - A hypothetical 100 basis point change in interest rates would affect interest income on investments by approximately $0.9 million for both 2024 and 2025 [480].

Core Viewpoint - Viking Therapeutics plans to advance its experimental oral obesity drug into late-stage trials later this year, indicating a significant step in its development pipeline [1]. Company Summary - Viking Therapeutics is focusing on the advancement of its oral obesity drug, which is currently in the experimental phase [1]. Industry Context - The move to late-stage trials reflects the growing interest and investment in obesity treatments within the pharmaceutical industry, as companies seek to address the rising prevalence of obesity globally [1].

Core Insights - Viking Therapeutics reported a quarterly loss of $1.38 per share, which was higher than the analyst estimate of a loss of 89 cents, indicating a significant miss in earnings expectations [2] - The increase in net loss was primarily attributed to a rise in research and development expenses, which totaled $153.5 million for the fourth quarter, compared to $31 million for the same period in 2024 [2] Group 1: Financial Performance - The increase in research and development expenses was mainly due to costs associated with clinical studies, stock-based compensation, and salaries and benefits, while there was a decrease in manufacturing expenses for drug candidates and preclinical studies [3] - The CEO of Viking, Brian Lian, highlighted that the past year was exceptional for the company, marked by rapid progress in their obesity portfolio [3] Group 2: Stock Performance - Viking Therapeutics stock experienced an increase of 8.58%, reaching a price of $31 during extended trading on Wednesday [4]

Core Insights - Viking Therapeutics reported strong financial results for Q4 and year-end 2025, with a cash position of $706 million and significant advancements in its obesity treatment pipeline [1][3] Financial Performance - Q4 2025 research and development expenses were $153.5 million, up from $31.0 million in Q4 2024, primarily due to increased clinical study costs [3] - General and administrative expenses decreased to $11.3 million in Q4 2025 from $15.3 million in Q4 2024 [3] - The net loss for Q4 2025 was $157.7 million, or $1.38 per share, compared to a net loss of $35.4 million, or $0.32 per share, in Q4 2024 [3] - For the full year 2025, research and development expenses totaled $345.0 million, compared to $101.6 million in 2024 [3] - The net loss for the year ended December 31, 2025, was $358.5 million, or $3.19 per share, compared to a net loss of $110.0 million, or $1.01 per share, in 2024 [3] Clinical Pipeline Updates - The Phase 3 VANQUISH trials for VK2735, a dual agonist for obesity, are ongoing, with VANQUISH-1 fully enrolled and VANQUISH-2 nearing completion [1][3] - VK2735's oral formulation is set to advance into Phase 3 trials in Q3 2026, following positive results from Phase 1 and Phase 2 studies [2][3] - A Phase 1 maintenance dosing study for VK2735 has been fully enrolled, with results expected in Q3 2026 [1][2] Upcoming Developments - The company plans to file an Investigational New Drug (IND) application for a novel amylin agonist this quarter, expanding its obesity treatment portfolio [1][3] - Viking is also developing a series of dual amylin and calcitonin receptor agonists (DACRAs) for obesity and metabolic disorders [4] Market Position and Strategy - VK2735 is positioned as a unique dual agonist with both subcutaneous and oral formulations, potentially improving treatment adherence and reducing side effects [2][3] - The company has established a comprehensive manufacturing and supply agreement for VK2735 to support its commercial activities [1][3]

Financial Performance - Viking reported a net loss of $157.7 million, or $1.38 per share, for Q4 2025, compared to a net loss of $35.4 million, or $0.32 per share, in Q4 2024[23]. - For the year ended December 31, 2025, Viking reported a net loss of $358.5 million, or $3.19 per share, compared to a net loss of $110.0 million, or $1.01 per share, in 2024, indicating a significant increase in net loss[26]. - The company reported a comprehensive loss of $358.47 million for the year ended December 31, 2025, compared to a comprehensive loss of $110.36 million in 2024[35]. Research and Development - Research and development expenses increased to $153.5 million for Q4 2025, up from $31.0 million in Q4 2024, primarily due to clinical studies and stock-based compensation[21]. - For the full year 2025, research and development expenses totaled $345.0 million, compared to $101.6 million in 2024, reflecting increased clinical study costs and regulatory services[24]. - Research and development expenses for the year ended December 31, 2025, were $344.96 million, up from $101.64 million in 2024, reflecting a substantial increase in investment in R&D[35]. Cash Position - Viking has a strong cash position of $706 million at the end of Q4 2025, supporting future milestones[4]. - As of December 31, 2025, Viking held cash, cash equivalents, and short-term investments totaling $706 million, down from $903 million as of December 31, 2024[27]. Clinical Trials and Studies - Viking completed enrollment in the VANQUISH-1 study with over 4,500 patients, exceeding the target ahead of schedule[9]. - The Phase 2 VENTURE study demonstrated statistically significant mean body weight reductions of up to 14.7% after 13 weeks of treatment[6]. - The Phase 1 study of VK2735 showed dose-dependent weight reductions of up to 8.2% after 28 days of daily dosing[11]. - The company is advancing VK2735, a dual agonist for metabolic disorders, currently in Phase 3 trials, with positive safety and efficacy data from earlier trials[30]. - Viking is also developing VK2809, which achieved primary and secondary endpoints in a Phase 2b study for non-alcoholic steatohepatitis (NASH) and fibrosis, demonstrating significant clinical benefits[30]. - Viking expects to report results from the VK2735 maintenance dosing study in Q3 2026[19]. Operating Expenses - The total operating expenses for the year ended December 31, 2025, were $393.34 million, compared to $150.92 million in 2024, indicating a sharp increase in overall expenditures[35]. - General and administrative expenses decreased to $48.4 million for the year ended December 31, 2025, from $49.3 million in 2024, primarily due to reduced legal and patent service costs[25]. Liabilities and Financial Obligations - Viking's total liabilities as of December 31, 2025, were $76.67 million, a significant increase from $28.04 million in 2024, reflecting growing financial obligations[37]. Product Development and Innovation - The company plans to advance oral VK2735 into Phase 3 development for obesity, expected to begin in Q3 2026[4]. - The company plans to file an IND for its novel amylin agonist this quarter, expanding its obesity treatment portfolio[4]. - The company is also exploring new dual amylin and calcitonin receptor agonists (DACRAs) for obesity and metabolic disorders, indicating ongoing innovation in its product pipeline[30].

Core Viewpoint - The article emphasizes the importance of conducting thorough research and independent verification before making investment decisions, highlighting the inherent risks and volatility associated with stock investments [2][3]. Group 1 - The article provides informational content but does not serve as an exhaustive analysis of any featured company [2]. - It clarifies that the predictions and opinions presented are based on a probabilistic approach rather than absolute certainty [2]. - The author has no stock or derivative positions in any of the companies mentioned and does not plan to initiate any such positions in the near future [1]. Group 2 - The article stresses that past performance is not indicative of future results, and no specific investment recommendations are provided [3]. - It notes that the views expressed may not reflect those of the platform as a whole, indicating a diversity of opinions among analysts [3]. - The article highlights that analysts may not be licensed or certified by any regulatory body, which could affect the reliability of the information presented [3].

Core Insights - Viking Therapeutics, Inc. is set to release its financial results for Q4 and year-end 2025 on February 11, 2026, after market close [1] - A conference call will be held on the same day at 4:30 p.m. Eastern Time to discuss these results and provide corporate updates [2] Company Overview - Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders [3] - The company is advancing several clinical programs, including VK2735, a dual agonist for GLP-1 and GIP receptors, currently in Phase 3 trials for obesity [3] - VK2809, another key program, is an orally available small molecule for treating lipid and metabolic disorders, having met primary and secondary endpoints in a Phase 2b study for NASH [3] - The company is also developing VK0214 for X-ALD, which has shown safety and efficacy in reducing VLCFAs in a Phase 1b trial [3]

Core Viewpoint - Investors are expected to focus on Viking Therapeutics' progress with VK2735, a dual agonist for obesity treatment, during the upcoming Q4 and full-year 2025 results announcement [1] Company Overview - Viking Therapeutics is developing VK2735 for obesity treatment, with no marketed drugs currently in its portfolio, leading to no expected revenues for the upcoming quarter [2] - The Zacks Consensus Estimate for Q4 earnings is a loss of 89 cents per share [2] Pipeline Development - VK2735 is being studied in multiple late-stage studies, including VANQUISH-1 and VANQUISH-2, for both oral and subcutaneous formulations [5] - The VANQUISH-1 study, completed in November 2025, evaluates VK2735 in obese adults with weight-related co-morbid conditions, while VANQUISH-2 focuses on obese or overweight adults with type II diabetes [6][7] Competitive Landscape - Eli Lilly and Novo Nordisk dominate the obesity treatment market with their GLP-1 injections, which may increase competitive pressure on Viking Therapeutics [9] - Novo Nordisk recently launched an oral version of Wegovy, and an FDA decision on Lilly's oral obesity pill is expected in the first half of 2026 [9] Financial Performance - Viking Therapeutics has a history of earnings surprises, missing estimates in the last four quarters with an average negative surprise of 21.66% [11] - The company currently has an Earnings ESP of 0.00%, indicating no expected earnings beat for the upcoming report [12][13] Future Updates - Further updates on VK2735, as well as the company's NASH and X-ALD programs, are anticipated during the upcoming earnings call [10][8]

Core Insights - Eli Lilly's stock experienced a significant increase of 39% over the past year, driven by the success of its weight loss drugs [1] - The obesity drug market is projected to reach nearly $100 billion by the end of the decade, indicating strong growth potential [2] Company Overview - Viking Therapeutics specializes in treatments for metabolic and endocrine disorders and is currently developing weight loss candidates in late-stage clinical trials [4] - The company's VK2735, available in both injectable and oral forms, functions similarly to Lilly's tirzepatide, targeting hormones that regulate blood sugar and appetite [5] Clinical Development - Viking's VK2735 has shown promising results in clinical trials, with a reported weight loss of up to 14.7% in a phase 2 trial after 13 weeks [5] - The drug is currently in phase 3 and phase 2 trials, indicating progress towards potential market entry [4] Market Competition - VK2735 has the potential to compete with established products like Lilly's tirzepatide and Novo Nordisk's semaglutide, although direct comparisons are challenging due to differing trial parameters [7] - Despite the dominance of major pharmaceutical companies, there is a consistent demand for weight loss drugs, suggesting opportunities for new entrants like Viking [8] Investment Potential - If successful, Viking Therapeutics could see substantial rewards due to the high demand for weight loss drugs and the potential for partnerships or acquisitions by larger companies [9] - The stock is considered a top biotech investment for 2026, appealing to investors willing to accept the risks associated with drug development [9]